---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-137165"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:54:54.934507+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharmaceuticals prices public offering of 6.875M shares at $8.00, expects net proceeds ~$58.2M

## Summary
- Public offering of 6.875M shares at $8.00/share; underwriters exercised overallotment for 1.031M additional shares in full.
- Net proceeds expected approx. $58.2M after underwriting discounts and expenses.
- Concurrent $5.0M private placement to Abingworth Bioventures at same $8.00/share, closing conditioned on public offering.
- Offering expected to close May 8, 2023; shares sold under effective S-3 shelf registration.
- Jefferies, BofA Securities, and Piper Sandler act as joint book-running managers.

## SEC filing metadata
- accession: 0001193125-23-137165
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/0001193125-23-137165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/d362041d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-137165
- JSON: https://secwatch.observer/filing/0001193125-23-137165.json
- Plain text: https://secwatch.observer/filing/0001193125-23-137165.txt

## Key facts
- Material Agreements
  OnKure Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at 6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n (effective 2023-05-03).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters
  - Value: 6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n
  - Effective: 2023-05-03
  source text: On May 3, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an offering (the “Public Offering”) of 6,875,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/0001193125-23-137165-index.htm
- Material Agreements
  OnKure Therapeutics, Inc. entered into Securities Purchase Agreement with Abingworth Bioventures 8 LP valued at 625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million (effective 2023-05-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Abingworth Bioventures 8 LP
  - Value: 625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million
  - Effective: 2023-05-02
  source text: On May 2, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Abingworth Bioventures 8 LP. (“Abingworth”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/0001193125-23-137165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.